Akebia Therapeutics' stock price has dropped, with the company reporting a loss in the first quarter and a plan to increase shares. The decline has resulted in a significant market cap drop, potentially prompting institutional owners to reconsider their positions. Analysts are updating their estimates for the company following its first-quarter results.